PIKFYVE and amyotrophic lateral sclerosis: Pharmacological suppression of PIKFYVE kinase activity has been reported to ameliorate pathology in animal and iPSC-derived motor neuron models of familial and sporadic ALS [432], and a number of PIKFYVE inhibitors are currently also being tested in ALS clinical trials [433, 434].